Sean Bohen (file photo)
November 1, 2020 03:08 PM ESTUpdated November 3, 11:07 AM
People
Financing
Bioregnum
Opinion

Sean Bo­hen just wrote the hand­book on how to make a quick for­tune in biotech

If you ask any­one in drug de­vel­op­ment about what mo­ti­vates them — or even if you don’t — you’re go­ing to get a reg­u­lar dou­ble-bar­reled blast about …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times